Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is
implicated in cancer and DNA damage response (DDR) pathways are in place against this …

Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent
in prostate cancer than previously recognized, with BRCA2 as the most commonly altered …

Despite chemotherapy and novel androgen‐receptor signalling inhibitors (ARSi) have been
approved during the last decades, metastatic castration‐resistant prostate cancer (mCRPC) …

Prostate cancer is globally the second most commonly diagnosed cancer type in men.
Recent studies suggest that mutations in DNA repair genes are associated with aggressive …

Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …

Abstract The US Food and Drug Administration recently approved two poly‐adenosine
diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of …

Prostate cancer (PC) is the second most common cancer in men worldwide. Due to the large-
scale sequencing efforts, there is currently a better understanding of the genomic landscape …

Prostate cancer (PCa) is the second most common neoplasm in men and the fifth leading
cause of death worldwide [1]. Despite recent advancements in the diagnosis and treatment …

Over the past years, several studies have demonstrated that defects in DNA damage
response and repair (DDR) genes are present in a significant proportion of patients with …

Several ongoing international prostate cancer (PC) clinical trials are exploring therapies that
target the DNA damage response (DDR) pathway. This systematic review summarizes the …